NASDAQ:CVET - Covetrus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.25
  • Forecasted Upside: 24.02 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$26.81
▲ +0.09 (0.34%)

This chart shows the closing price for CVET by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Covetrus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVET and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVET

Analyst Price Target is $33.25
▲ +24.02% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Covetrus in the last 3 months. The average price target is $33.25, with a high forecast of $48.00 and a low forecast of $20.00. The average price target represents a 24.02% upside from the last price of $26.81.

This chart shows the closing price for CVET for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Covetrus. This rating has held steady since August 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/31/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2021Raymond JamesBoost Price TargetOutperform$31.00 ➝ $39.00High
2/17/2021BarclaysInitiated CoverageOverweight$48.00Low
11/11/2020Credit Suisse GroupBoost Price TargetNeutral$17.00 ➝ $20.00Medium
10/21/2020Raymond JamesBoost Price TargetOutperform$26.00 ➝ $31.00High
9/16/2020Stifel NicolausUpgradeHold ➝ Buy$23.00 ➝ $26.00High
9/10/2020Raymond JamesReiterated RatingBuyMedium
8/12/2020Credit Suisse GroupBoost Price TargetNeutral$12.00 ➝ $14.00High
8/12/2020Stifel NicolausBoost Price TargetHold$20.00 ➝ $23.00High
8/12/2020Raymond JamesBoost Price TargetOutperform$14.00 ➝ $26.00High
7/30/2020Stifel NicolausBoost Price TargetHold$11.00 ➝ $20.00High
5/22/2020Credit Suisse GroupBoost Price TargetNeutral$10.00 ➝ $12.00Low
4/23/2020Credit Suisse GroupLower Price TargetNeutral$13.00 ➝ $10.00High
3/4/2020Credit Suisse GroupBoost Price TargetNeutral$11.00 ➝ $13.00High
10/17/2019Credit Suisse GroupLower Price TargetNeutral$15.00 ➝ $11.00High
9/9/2019The Goldman Sachs GroupInitiated CoverageSell$11.00High
8/16/2019Credit Suisse GroupSet Price TargetHold$15.00Low
8/15/2019Raymond JamesLower Price TargetOutperform$45.00 ➝ $21.00High
8/14/2019Stifel NicolausLower Price TargetHold$30.00 ➝ $18.00High
5/23/2019GuggenheimInitiated CoverageNeutralHigh
5/22/2019Stifel NicolausInitiated CoverageHold ➝ Hold$30.00High
5/10/2019Cleveland ResearchInitiated CoverageHoldHigh
4/4/2019Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$35.00Low
3/20/2019SVB LeerinkReiterated RatingOutperformHigh
2/27/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$45.00High
2/12/2019William BlairInitiated CoverageOutperform ➝ OutperformN/A
(Data available from 6/24/2016 forward)
Covetrus logo
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.
Read More

Today's Range

Now: $26.81
Low: $26.54
High: $27.16

50 Day Range

MA: $27.78
Low: $25.24
High: $30.86

52 Week Range

Now: $26.81
Low: $16.97
High: $40.78

Volume

504,714 shs

Average Volume

748,697 shs

Market Capitalization

$3.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Covetrus?

The following equities research analysts have issued reports on Covetrus in the last year: Barclays PLC, Credit Suisse Group AG, Raymond James, Stifel Nicolaus, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CVET.

What is the current price target for Covetrus?

4 Wall Street analysts have set twelve-month price targets for Covetrus in the last year. Their average twelve-month price target is $33.25, suggesting a possible upside of 24.4%. Barclays PLC has the highest price target set, predicting CVET will reach $48.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $20.00 for Covetrus in the next year.
View the latest price targets for CVET.

What is the current consensus analyst rating for Covetrus?

Covetrus currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CVET will outperform the market and that investors should add to their positions of Covetrus.
View the latest ratings for CVET.

What other companies compete with Covetrus?

How do I contact Covetrus' investor relations team?

Covetrus' physical mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company's listed phone number is 888-280-2221 and its investor relations email address is [email protected] The official website for Covetrus is www.henryscheinvet.com.